Heska (NASDAQ:HSKA)‘s stock had its “buy” rating reiterated by equities researchers at Canaccord Genuity in a research report issued on Wednesday, November 6th, The Fly reports. They currently have a $105.00 target price on the medical research company’s stock, up from their prior target price of $75.00. Canaccord Genuity’s price target suggests a potential upside of 13.86% from the stock’s previous close.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
A number of other equities research analysts also recently issued reports on HSKA. BidaskClub upgraded shares of Heska from a “hold” rating to a “buy” rating in a report on Thursday, October 31st. Zacks Investment Research downgraded shares of Heska from a “buy” rating to a “hold” rating in a report on Thursday, October 24th. ValuEngine upgraded shares of Heska from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Finally, Piper Jaffray Companies began coverage on shares of Heska in a research note on Wednesday, September 18th. They set a “neutral” rating and a $68.00 price objective for the company. One research analyst has rated the stock with a sell rating, six have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $85.75.
Shares of Heska stock traded up $1.36 during trading hours on Wednesday, reaching $92.22. The stock had a trading volume of 169,700 shares, compared to its average volume of 101,058. The company has a current ratio of 8.52, a quick ratio of 6.80 and a debt-to-equity ratio of 0.31. Heska has a twelve month low of $62.47 and a twelve month high of $105.00. The stock’s 50 day moving average is $78.03 and its 200 day moving average is $76.79. The firm has a market capitalization of $711.28 million, a PE ratio of 64.94 and a beta of 1.06.
Heska (NASDAQ:HSKA) last announced its earnings results on Tuesday, November 5th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). The company had revenue of $31.24 million during the quarter, compared to analysts’ expectations of $30.44 million. Heska had a net margin of 3.15% and a return on equity of 3.17%. As a group, sell-side analysts predict that Heska will post 0.05 earnings per share for the current year.
Several hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its holdings in Heska by 1,229.0% in the second quarter. JPMorgan Chase & Co. now owns 21,876 shares of the medical research company’s stock valued at $1,834,000 after acquiring an additional 20,230 shares in the last quarter. Conestoga Capital Advisors LLC raised its holdings in shares of Heska by 26.2% during the second quarter. Conestoga Capital Advisors LLC now owns 3,395 shares of the medical research company’s stock worth $289,000 after purchasing an additional 705 shares during the period. Susquehanna International Group LLP acquired a new stake in shares of Heska during the second quarter worth $219,000. State of New Jersey Common Pension Fund D raised its holdings in shares of Heska by 184.0% during the third quarter. State of New Jersey Common Pension Fund D now owns 28,400 shares of the medical research company’s stock worth $2,013,000 after purchasing an additional 18,400 shares during the period. Finally, Swiss National Bank raised its holdings in shares of Heska by 2.3% during the second quarter. Swiss National Bank now owns 13,400 shares of the medical research company’s stock worth $1,141,000 after purchasing an additional 300 shares during the period. Institutional investors and hedge funds own 93.73% of the company’s stock.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
Featured Story: Are sell-side analysts objective?